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Abstract. Background: The chemokine-chemokine receptor
(CR) network is involved in the regulation of cellular
infiltration of tumours. Cancer cells and infiltrating
macrophages produce a whole range of chemokines. This
study explored the expression of some CR and chemokine
production by cord blood stem cell-derived CD34+
monocytes and their novel CD14++CD16+ and
CD14+CD16– subsets in response to tumour cells. Material
and Methods: CR expression was determined by flow
cytometry and their functional activity by migration to
chemoattractants. Monocytes were cultured with tumour cells
and the chemokine content was assessed in culture
supernatants. Results: CD14++CD16+ monocytes exhibited
increased expression of chemokine (C-C) receptor (CCR) 1,
while CD14+CD16– of CCR2, chemokine (C-X-C) receptor
(CXCR) 1, 2 and 4. The increased expression of CCR2 on
CD14+CD16– monocytes was associated with their enhanced
migration to monocyte chemoattractant protein–1 (CCL2),
MCP-3 (CCL7), MCP-2 (CCL8) and MCP-4 (CCL13), while
that of CXCR1 and 2 to interleukin 8 (CXCL8), and CXCR4
to stromal cell-derived factor-1 (CXCL12). Tumour cells
induced production of macrophage inflammatory protein-1α
(CCL3) MIP-1β and regulated on activation normal T-cells
expressed and secreted (CCL5) but not CCL2 or CXCL8,
monokine induced by gamma interferon (CXCL9), interferon
gamma-induced protein 10 (CXCL10). Conclusion: The
studied monocyte subsets, in comparison to those from blood,
exhibit different expression of CRs and response to the
stimuli that occur from tumour cells.
The chemokine–chemokine receptor (CR) network is involved
in the regulation of leukocyte infiltration of tumours.
Leukocytes, including monocytes, migrate to the tumour via
the gradient of chemokines that are produced by tumour and
stromal cells, including monocyte-derived macrophages (1-4).
Several chemokines are found in the tumour microenvironment
and are involved in the regulation of tumour-infiltrating
macrophages (TIMs), by controlling their directed migration to
the tumour and inhibiting their egress by regulation of
angiogenesis and immune response to tumour cells and by
controlling tumour cell movements, which is the first step in
local tumour spread and metastasis (1). Chemokines that are
found within the tumour microenvironment include: monocyte
chemoattractant protein-1 (CCL2), macrophage inflammatory
protein 1α (CCL3) and 1β (CCL4), regulated on activation
normal T-cells expressed and secreted (CCL5), MCP-2
(CCL8), interleukin 8 (CXCL8), monokine induced by gamma
interferon (CXCL9), interferon gamma induced protein 10
(CXCL10), stromal cell-derived factor-1 (CXCL12) and many
others (1, 3, 4). In various types of tumors, production of a
different range of chemokines occurs and there is no selectivity
in their release, either by tumour cells or by TIMs. Many CRs
are abundantly expressed on cancer cells and TIMs (1). CCR1
is mainly expressed on TIMs, while CCR7 is expressed on
tumour cells (5). From this brief description, it becomes clear
that very sophisticated chemokine–CR interactions occur in the
tumours, which both foster and inhibit tumour growth and
which are central to the regulation of immune response to
cancer cells (1, 6). In tumours, the situation is further
complicated by polarization of TIMs from M1 to M2
mononuclear phagocytes which exhibit different expressions of
CR and production of chemokines (7).
During interactions with tumour cells and their tumour-
derived microvesicles (TMVs), peripheral blood (PB)
monocytes, which are precursors of TIMs, produce several
chemokines (8). Two major subpopulations of PB
monocytes: CD14++CD16– (classical monocytes) and
CD14+CD16++ (non-classical monocytes) (9) exhibit
different expression of CRs (10). 
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We have previously described the protocol for the
generation of monocytes from cord blood (CB)
haematopoietic CD34+ progenitors and provided evidence
that these monocytes and their novel CD14++CD16+ and
CD14+CD16– subsets differ phenotypically and functionally
from blood monocytes (11). On this background we wished
to investigate the expression and function of CRs and the
production of chemokines by CB CD34+ stem cell-derived
monocytes and their subsets. Stimulation with cancer cells
was used to mimic the tumour microenvironment.
Materials and Methods
Isolation and culture of CD34+ cells. CD34+ cells were isolated
using the EasySep Human CD34 Positive Selection Kit (StemCell
Technologies, Vancouver, Canada) based on magnetic cell sorting
from CB mononuclear cells obtained by standard density-gradient
centrifugation. CD34+ cells were expanded and differentiated to
monocytes in two-step cultures in 24-well plates (Sarstedt,
Numbrecht, Germany), as previously described (11). Firstly, the
cells were expanded for 7-10 days by culturing 1×105 CD34+
cells/well/ml in the expansion medium: X-VIVO 10 medium
(BioWhittaker, Verviers, Belgium) supplemented with 4% of foetal
bovine serum (FBS; Gibco, Paisley, UK) and recombinant human
stem cell factor (SCF, 50 ng/ml), thrombopoietin (TPO, 15 ng/ml),
interleukin (IL)-3 (30 ng/ml) and Fms-related tyrosine kinase 3
ligand (FLT-3L, 30 ng/ml), all from PeproTech (London, UK). Then
cells were harvested and seeded at 1×105/ml in the differentiation
medium: Iscove’s Modified Dulbecco’s Medium (IMDM; Gibco)
with 20% of FBS and SCF (25 ng/ml), macrophage colony-
stimulating factor (M-CSF; 30 ng/ml, PeproTech), IL-3 (30 ng/ml)
and FLT-3L (30 ng/ml), and cultured for 7-10 days.
Isolation of monocyte subpopulations. Cells cultured in the
differentiation medium were harvested, washed, and suspended at a
density of 10×106/ml in phosphate buffered saline (PBS; Gibco).
After staining with anti-CD14 allophycocyanin (APC) and anti-
CD16 phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs;
both from BD Pharmingen San Diego, CA, USA), cells were sorted
into CD14+ (total monocytes), CD14++CD16+ and CD14+CD16–
populations in a fluorescence-activated cell sorter FACS Aria II (BD
Biosciences, Immunocytometry Systems, San Jose, CA, USA), using
a 100 μm nozzle tip. Sorted cells were collected into polystyrene
Falcon 2057 tubes (BD Biosciences) pre-coated with FBS to avoid
plastic charging and cell attachment to the wall.
Analysis of CR expression. The expression of CRs on monocytes
was performed by three-colour flow cytometric analysis after
staining with the following PE-conjugated (BD Pharmingen) mAbs
against: chemokine (C-C) receptor (CCR) 1, 3, 5 and 7; chemokine
(C-X-C) receptor (CXCR) 1, 2 and 4; and PE-conjugated mAb to
CCR2 (R&D, Minneapolis, MN, USA), allophycocyanin (APC)-
conjugated anti-CD14 and PE-Cyanine 5 (PE-Cy5)-conjugated anti-
CD16. In parallel, staining with appropriate isotype-matched mouse
immunoglobulins were used as negative controls. After incubation
for 30 min at 4˚C with mAb or isotype controls,monocytes were
washed, re-suspended in 0.3 ml of phosphate buffred saline (PBS)
containing 0.1% sodium azide and analysed by flow cytometry
(FACS Canto; BD Biosciences) using the FACS Diva software. List
mode data for 20,000 events were acquired and statistical analysis
was performed according to green, orange or red fluorescence of
cells stained with isotype controls.
Migration to tumour-derived chemoattractants. Costar Transwell 24-
well plates with 8-μm pore-size filter (Costar Corning, Cambridge,
MA, USA) were used for chemotactic assays. RPMI-1640 medium
(PAA Laboratories, Pasching, Germany) supplemented with 0.5%
bovine serum albumin (Sigma, St. Louis, MO, USA) (control) or with
the addition of CCL2, 3, 7, 8, 13, 19 or CXCL8 or 12, (all at 100
ng/ml; PeproTech) in a final volume of 650 μl was added to the lower
chamber. Monocytes (CD14+) and subpopulations (CD14++CD16+
and CD14+CD16–) were placed in the upper chamber (1×105/100 μl).
As controls, 2×104 cells (i.e. 20% of these in the upper chamber)
were put into the lower chamber. After 4 h, the cells in the lower
chamber of the Transwell were harvested and their number was
determined by flow cytometry. The cells were gated according to their
forward scatter (FSC)/side scatter (SSC) parameters and counted
during 20 s acquisition time at a high-flow rate. Data are expressed as
the percentage of migrating cells according to the formula:
Number of cells in the test well ×20% 
migrating cells (%)= 
Number of cells in the control well 
Determination of chemokine production. The total population of
CD14+ monocytes and their subpopulations were cultured in flat-
bottom 96-microtitre plates (Nunc, Roskilde, Denmark) at
1×105/100 μl/well in RPMI-1640 medium with 5% FBS. Cells were
cultured alone or were stimulated with human pancreatic carcinoma
cells (HPC-4) cultured, as previously described (12), at a ratio of
1:0.3 for 18 h at 37˚C in a humidified atmosphere with 5% CO2.
The concentrations of chemokines (CCL2-5 and CXCL8-10) in the
supernatants were measured using the FlexSet system (BD
Biosciences) followed by flow cytometric analysis (FACS Canto).
The FlexSet beads were discriminated in FL-4 and FL-5 channels,
while the concentration of specified chemokines was determined by
the intensity of FL-2 fluorescence, using the respective standard
reference curve and FCAP Array software (BD Biosciences). For all
chemokines, the detection level was 10 pg/ml. 
Statistical analysis. Non-parametric one-way ANOVA test with the
use of Microcal Origin version 5.0 software (Northampton, MA,
USA) was used for the analysis. Differences were considered
significant at p<0.05. 
Results
Expression of CRs on monocyte subsets. It is well-established
that monocytes arriving at the tumour site interact with
tumour-associated chemokines (1) and that blood monocytes
differ in the expression of some CRs (10). We studied the
expression of some CRs, mostly those which interact with
chemokines produced by tumour cells, on monocyte subsets
CD14++CD16+ and CD14+CD16– generated from CB CD34+
stem cells. Table I shows that CCR3 and 5 and CXCR1 were
mostly expressed on the CD14++CD16+ subset, as judged by
mean fluorescence intensity (MFI), and CCR1 was mostly
expressed on the CD14++CD16+ both as percentage of positive
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cells and as MFI. The CD14+CD16– monocytes exhibited a
higher number of CCR2-, CXCR1-, 2-, and 4-expressing cells.
CCR7 was not detected on either subpopulation. 
Migration to tumour cell-derived chemokines. It is well-
known that PB monocytes are attracted to the tumour site by
chemokines, and are kept there by chemotactic inhibitory
proteins that are produced by tumour or inflammatory cells
in the local microenvironment. Therefore, the migration of
monocytes to some products of cancer cells was studied
(Table II). CD14+ cells exhibited a range of degrees of
chemotaxis, but migrated to all chemokines. Comparison of
both subsets revealed significantly higher migration of
CD14+CD16– cells to CCL2, 7, 8, 13 and CXCL8 and 12,
which are produced by cancer cells (1). Chemotaxis of
CD14++CD16+ cells was lower than that of the total
population of CD14+ cells.
Production of chemokines. The CD14+ monocytes (total
population) and their subpopulations were cultured for 18 h
in medium, or stimulated with HPC-4 tumour cells and the
chemokine content in the culture supernatants was
determined. No induction of expression of CCL2 or CXCL8-
10 by tumour cells was observed (data not shown). No
difference in the spontaneous production of CCL3 and -5
between the subsets was observed, but CCL4 release by
CD14+CD16– cells was lower. Tumour cells stimulated
CCL3-5 production by CD14+ monocytes and their subsets,
but there was no difference between them (Figure 1A-C). 
Discussion
It is well-established that the chemokine-CR network plays an
important role in cancer, infection and inflammation (1, 4). In
the present study, the CR pattern and chemokine production
exhibited by novel monocyte subsets CD14++CD16+ and
CD14+CD16– generated from CB CD34+ haematopoietic stem
cells, were determined. As it is unestablished whether the
number of positive cells or the MFI is important, and to our
knowledge, there is a difference between these parameters
within a given cell population, no clear conclusions about the
receptor expression can be made. Therefore, we presented
both the percentages of CR-expressing cells and the MFI. This
study showed that CD14++CD16+ cells were characterized by
an enhanced expression of CCR1 (percentage of positive cells
and MFI) and CCR3 and 5 and CXCR1 (MFI only). The
CD14+CD16– subset contained an increased percentage of
CCR2-, CXCR1-, 2- and 4-positive cells. CCR7 was not
expressed by either subset, although it is known that it is
abundantly expressed on polarized M1 macrophages (7). Our
findings provide further evidence that these monocyte subsets
are clearly different from that of PB monocytes, as CCR2 is
mostly expressed on blood CD14++CD16– cells and CCR5 on
CD14+CD16++ monocytes, with equivalency of CCR1
expression on both subsets (10). The only consistently
expressed CCR on TIMs is CCR1 in ovarian cancer (1, 5), but
it is unknown whether it is limited to a particular macrophage
subset. It is also unknown whether monocytes/macrophages
are generated in situ from CD34+ progenitors. Furthermore,
there is a dynamic variation in the cycling of haematopoietic
stem cells in steady-state and inflammation (17). 
CR expression is a pre-requisite for recruitment of blood
monocytes to the tumour and inflammatory sites and is
governed by a whole range of chemokines, mostly by CCL2
(1, 10), but also by CCL12, which is produced by cancer cells
(1). Hence, CXCR4 expression is important for migration of
monocytes to the tumour site. Furthermore, the CXCR4-
CXCL12 axis is also involved in tumour progression,
angiogenesis and metastasis (14). CCR1 and CXCR2 may also
be involved as their ligands CCL1, 3 and 5, and CXCL8,
respectively, are abundantly produced by cancer and
inflammatory cells (4, 7, 15). Therefore, the expression of
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Table I. Expression of chemokine receptors on monocyte subsets. Data
represent the mean±SD from six independent experiments.
Receptor CD14++CD16+ CD14+CD16–
% MFI % MFI
CCR1 14±6a 485±226a 4.3±2.5 63.5±43.6 
CCR2 4.8±2.7 499±193 38.7±28b 364±301
CCR3 15±14 567±323a 9.7±6.4 86±17
CCR5 3.1±1.7 594±355a 1.97±1.2 280±195 
CCR7 1.32±1.28 360±284 0.48±0.4 51±3.5
CXCR1 8.3±2.2 256±168a 29±8.6a 26±9 
CXCR2 3.5±1.8 318±173 31±6.4a 399±155
CXCR4 6.1±3.7 498±17 68±9.6a 1241±262a
aSignificantly different between the subsets at p<0.05, bat p=0.055.
Table II. Migration of monocytes and their subsets to some chemokines.
Data are expressed as the percentage of migrating cells. The mean±SD
from four different experiments is shown.
CD14+ CD14++CD16+ CD14+CD16–
CCL2 20±8 2.5±2.7 20±17a
CCL7 53±30 6±3 51±28a
CCL8 12±7 1.9±1.9 31±18a
CCL13 54±31 1.5±0.6 46±21a
CCL19 5.6±4.7 5.6±4.7 2.3±2.1
CXCL8 29±16 13±5 40±16a
CXCL12 7.5±5 19.2±1.4 33.8±8a
aSignificantly different from CD14++CD16+ cells.
relevant CRs is crucial for interactions with appropriate
ligands. For migration studies the chemokines that are
produced by tumour cells (CCL2, 7, 8, 13 and 19, and CXCL8
and 12) were chosen. The increased percentage of CCR2-, and
CXCR1-, 2- and 4-positive cells within the CD14+CD16–
population was in keeping with the enhanced migration of this
subset to the appropriate ligands. Thus, expression of CCL2,
7, 8 and 13 which are ligands of CCR2, CXCL8, ligand of
CXCR1 and 2 and CXCR4, ligand of CXCL12, were
observed. It indicates that these CRs are of functional
relevance. There was no difference between the subsets in the
migration to CCL19, for which CCR7 receptor was virtually
absent and chemotaxis was very low. However, it should be
noted that CRs are not always selective for a given chemokine,
and more than one CR may exist for several chemokines.
Thus, CCR1 interacts with CCL2, 3, 5 and 7, and CCR5 with
CCL3, 4 and 5, while CXCL8 with both CXCR1 and 2 (16).
Surprisingly, CD14++CD16+ cells which exhibited an
increased expression (MFI) of CCR1, 3 and 5, and CXCR1,
did not migrate to CCL2, 7, 8, 13 and 19. There are two
possible explanations for this. Either MFI determination is not
a good marker for the chemotactic ability of cells, or simply,
as these CD14++CD16+ monocytes are larger (11) and more
adherent to human umbilical vein endothelial cells
(unpublished observation), their movement is limited. Hence,
according to our data, the number of CR-positive cells, rather
than the magnitude of their expression, as defined by MFI,
seems to be the decisive factor for the chemotactic ability of a
given cell population. Based on the functional data, we wish to
suggest that CD14++CD16+ monocytes are characterized by
enhanced CCR2 expression, while CD14+CD16– cells by
increased CCR2, and CXCR1, 2 and 4. CRs and their
chemotactic ligands play a number of roles in several steps of
tumour metastasis, including adherence of cancer cells to
vascular endothelium, extravasation from blood vessels,
metastatic colonization, angiogenesis and proliferation (17).
Therefore, these observations, indicating differences in
expression of CRs on the studied monocytes subsets, may
further support the existence of complicated chemokine-CR
networks operating in cancer.
As stated above, chemokines are produced at
inflammatory and tumour sites, not only by cancer cells but
also by TIMs. Hence, to mimic this situation we also studied
the production of chemokines by monocytes stimulated with
tumour cells by which they are affected in situ. Tumour cells
induced the production of CCL3, 4 and 5. A whole spectrum
of chemokines is found in the tumour microenvironment and
play different roles in cancer (1). At the tumour site, TIMs
are the major producers of CCL3, 4 and 5 (1). At the invasive
site, macrophages enhance tumour cell migration and
invasion through their secretion of chemotactic factors (18).
It becomes clear that several chemokines produced within
tumour may attract blood monocytes that give rise to TIMs.
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Figure 1. Production of chemokines by monocytes and their
subpopulations following stimulation with tumour cells: Chemokine
CCL3 (A), CCL4 (B), CCL5 (C). Chemokine concentrations in the
culture supernatants were analysed using BD™ FlexSet System. Data
from five independent experiments are shown and expressed as the
mean±SD. *Significantly different from unstimulated monocytes.
Recently, it has been demonstrated that solid head and neck
cancer is infiltrated by CD34+ stem cells and that when these
are isolated from CB, following stimulation with these
cancer cells, the CD34+ cells produced IL-6, known to exert
pro- and anti-inflammatory activities (19). Since stem cells
can multiply into different types of cell (20), the generation
of monocytes or TIMs in situ cannot be excluded. The
present study may provide some insight into the behavior of
stem cell-derived monocytes/TIMs within the tumour. 
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